A study into the automation of cognitive assessment tasks for delivery via the telephone: Lessons for developing remote monitoring applications for the elderly

D’Arcy, Shona; Rapčan, Viliam; Gali, Alessandra; Burke, Nicola; O'Connell, Gloria Crispino; Robertson, Ian H.; Reilly, Richard B.

doi:10.3233/thc-130740

Cited by 8 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recent research has suggested that remote (i.e., delivered via online or via mail) assessments are both acceptable and feasible for many participants and study partners (Geddes et al, 2020). Remote assessment has not only been shown to be feasible in young, cognitively unimpaired individuals, but also in older individuals with and without neurological and/or psychiatric disorders (D'Arcy et al, 2013;George et al, 2016;Wadsworth et al, 2016;Jacobs et al, 2021;Lavigne et al, 2021). For impaired participants, remote assessment might be preferred to reduce participant and study-partner burden as traveling into clinic becomes more physically challenging.…”

Section: Introductionmentioning

confidence: 99%

Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms

Munro

Buckley

Vannini

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

Whereas discrepancies between participant- and study partner-reported cognitive concerns on the Alzheimer’s disease (AD) continuum have been observed, more needs to be known regarding the longitudinal trajectories of participant- vs. study partner-reported concerns, particularly their relationship to AD biomarkers and mood symptomology. Additionally, it is unclear whether years of in-clinic data collection are needed to observe relationships with AD biomarkers, or whether more frequent, remote assessments over shorter periods of time would suffice. This study primarily sought to examine the relationships between longitudinal trajectories of participant- and study partner-rated cognitive decline and baseline biomarker levels [i.e., amyloid and tau positron emission tomography (PET)], in addition to how mood symptomatology may alter these trajectories of concerns over a 2-year period. Baseline mood was associated with longitudinal participant-rated concerns, such that participants with elevated depression and anxiety scores at baseline had decreasing concerns about cognitive decline over time (fixed estimate = −0.17, 95% CI [−0.29 to −0.05], t = −2.75, df = 457, adj. p = 0.012). A significant interaction between baseline amyloid (fixed estimate = 4.07, 95% CI [1.13–7.01], t = 2.72, df = 353, adj. p = 0.026) and tau (fixed estimate = 3.50, 95% CI [0.95–6.06], t = 2.70, df = 331, adj. p = 0.030) levels was associated with increasing study partner concerns, but not participant concerns, over time. The interaction between amyloid and study partner concerns remained significant when utilizing only the first year of concern-related data collection. Overall, these results suggest that frequent, remote assessment of study partner-reported concerns may offer additional insight into the AD clinical spectrum, as study partners appear to more accurately update their concerns over time with regard to pathology, with these concerns less influenced by participants’ mood symptomatology.

show abstract

Section: Introductionmentioning

confidence: 99%

Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms

Munro

Buckley

Vannini

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“… e ++ indicates public domain. – indicates that the test has been commercialized, including cases using automatic speech recognition technology 47,49 and cases where we are unsure if the company is still active 44 …”

Section: Introductionmentioning

confidence: 99%

Validation of SATURN, a free, electronic, self‐administered cognitive screening test

Bissig

Kaye

Erten-Lyons³

2020

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

Background Cognitive screening is limited by clinician time and variability in administration and scoring. We therefore developed Self‐Administered Tasks Uncovering Risk of Neurodegeneration (SATURN), a free, public‐domain, self‐administered, and automatically scored cognitive screening test, and validated it on inexpensive (<$100) computer tablets. Methods SATURN is a 30‐point test including orientation, word recall, and math items adapted from the Saint Louis University Mental Status test, modified versions of the Stroop and Trails tasks, and other assessments of visuospatial function and memory. English‐speaking neurology clinic patients and their partners 50 to 89 years of age were given SATURN, the Montreal Cognitive Assessment (MoCA), and a brief survey about test preferences. For patients recruited from dementia clinics (n = 23), clinical status was quantified with the Clinical Dementia Rating (CDR) scale. Care partners (n = 37) were assigned CDR = 0. Results SATURN and MoCA scores were highly correlated ( P < .00001; r = 0.90). CDR sum‐of‐boxes scores were well‐correlated with both tests ( P < .00001) ( r = −0.83 and −0.86, respectively). Statistically, neither test was superior. Most participants (83%) reported that SATURN was easy to use, and most either preferred SATURN over the MoCA (47%) or had no preference (32%). Discussion Performance on SATURN—a fully self‐administered and freely available (https://doi.org/10.5061/dryad.02v6wwpzr) cognitive screening test—is well‐correlated with MoCA and CDR scores.

show abstract

Basic Services Reach Out Towards Under-Served Populations

Wetter

2016

Health Informatics

View full text Add to dashboard Cite

A study into the automation of cognitive assessment tasks for delivery via the telephone: Lessons for developing remote monitoring applications for the elderly

Cited by 8 publications

References 19 publications

Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms

Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms

Validation of SATURN, a free, electronic, self‐administered cognitive screening test

Basic Services Reach Out Towards Under-Served Populations

Contact Info

Product

Resources

About